(Q34747443)

4 August 2017

1 reference

title

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation (English)

1 reference

4 August 2017

1 reference

Ronald M Bukowski

1

1 reference

4 August 2017

Craig Tendler

2

1 reference

4 August 2017

David Cutler

3

1 reference

4 August 2017

Esther Rose

4

1 reference

4 August 2017

Mark M Laughlin

5

1 reference

4 August 2017

Paul Statkevich

6

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

4 August 2017

1 reference

4 August 2017

95

1 reference

4 August 2017

2

1 reference

4 August 2017

389-396

1 reference

Biomedical and biotechnological applications of PEG- and PM-modified proteins

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

Pegaspargase: an alternative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

Long-acting growth hormones produced by conjugation with polyethylene glycol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

Objective antiviral assay of the interferons by computer assisted data collection and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

7 January 2021

Identification of the major positional isomer of pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

7 January 2021

The generation of electric currents in cardiac fibers by Na/Ca exchange

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

7 January 2021

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

7 January 2021

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10663

7 January 2021

Identifiers

DOI

10.1002/CNCR.10663

1 reference

4 August 2017

1 reference